Multiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group:One milligram pill will take clemastine fumarate every 12 hours for 12 weeks. Intervention 2: Control group:The placebo is taken every 12 hours for 12 weeks.
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: inclusion criteria : To sign the consent form knowingly. At the same time,not in another clinical study. The patient is between 18-50 years old. only have a secondery recurrent MS.
Exclusion criteria
Exclusion criteria: The patient is pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: baseline,three months after the start of intervention. Method of measurement: Questionnaire.;Symptoms. Timepoint: baseline, three months after the start of intervention. Method of measurement: Examination and diagnostic procedures. | — |
Secondary
| Measure | Time frame |
|---|---|
| IgG antibody. Timepoint: baseline and three months after the start of intervention. Method of measurement: elisa.;IgE antibody. Timepoint: baseline and three months after the start intervention. Method of measurement: elisa.;Brain and Spinal Cord Plaques. Timepoint: baseline and three months after the start of intervention. Method of measurement: MRI.;IgE antibody. Timepoint: baselines and three months after the start intervention. Method of measurement: elisa. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTayyebe zamani
Bagheiat-allah University of Medical Sciences
Outcome results
None listed